Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management

Use of immune checkpoint inhibitors (ICI) is increasing in patients with oncologic disease. Three classes of checkpoint inhibitors exist: anti-PD1 (nivolumab, pembrolizumab), anti-CTLA4 (ipilimumab), and anti-PDL1 (atezolizumab, avelumab, durvalumab). ICI therapy has been used in multiple malignanci...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubair, Adeel S, Roy, Bhaskar, Baehring, Joachim M, Nowak, Richard J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683636/
https://www.ncbi.nlm.nih.gov/pubmed/36439604
http://dx.doi.org/10.7759/cureus.30638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683636/
https://www.ncbi.nlm.nih.gov/pubmed/36439604
http://dx.doi.org/10.7759/cureus.30638

Ejemplares similares